Suppr超能文献

糖尿病肾病不伴白蛋白尿:糖尿病肾病中的一个新实体。

Diabetic Kidney Disease Without Albuminuria: A New Entity in Diabetic Nephropathy.

机构信息

Firoozgar Clinical Research Development Center, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.

出版信息

Iran J Kidney Dis. 2024 Jan;1(1):1-8.

Abstract

Non-albuminuric diabetic kidney disease (NA-DKD) is characterized by progressive loss of kidney function with an annual loss of estimated glomerular filtration rate (eGFR) more than 3 mL/ min/ 1.73m2 per year. NA-DKD is also associated with the late manifestation of diabetic kidney disease, characterized by reduced eGFR (< 60 mL/min/ 1.73m2), in the absence of albuminuria (urine albumin-to-creatinine ratio [UACR] less than 30 mg/g. The typical glomerular changes seen in diabetic nephropathy are less frequently observed in normoalbuminuric patients, while they predominantly show mesangial expansion and tubulointerstitial and vascular changes. The prevalence of NA-DKD has been increasing during the past decade, with a wide range of prevalence in different studies. It seems that patients with NA-DKD are more likely to be female and have better metabolic profile including a lower Hb A1c, lower triglyceride, lower cholesterol, lower BMI and systolic blood pressure, and lower rate of retinopathy. Compared to patients with albuminuria, those with NA-DKD show a lower risk for progression to end-stage kidney disease (ESKD), or rapid decline in eGFR. They also have increased risks of death and hospitalization for heart failure compared with non-DKD diabetic patients, but a lower risk in comparison with albuminuric DKD, regardless of GFR. There is no effective treatment for this phenotype of the disease, but limited data support the use of SGLT2 inhibitors to slow chronic kidney disease progression along with appropriate metabolic risk factor control. More clinical research and pathologic studies are needed for a better understanding of the phenotype, prevention, and treatment methods of the disease.  DOI: 10.52547/ijkd.7966.

摘要

非白蛋白尿型糖尿病肾病(NA-DKD)的特征是肾功能进行性丧失,估算肾小球滤过率(eGFR)每年超过 3 mL/min/1.73m2。NA-DKD 也与糖尿病肾病的晚期表现有关,其特征为 eGFR 降低(<60 mL/min/1.73m2),而尿白蛋白与肌酐比值(UACR)<30 mg/g。在正常白蛋白尿患者中,较少观察到糖尿病肾病中典型的肾小球变化,而主要表现为系膜扩张以及肾小管间质和血管变化。在过去十年中,NA-DKD 的患病率一直在增加,不同研究中的患病率差异很大。似乎 NA-DKD 患者更可能是女性,且代谢状况更好,包括更低的 HbA1c、更低的甘油三酯、胆固醇、BMI 和收缩压,以及更低的视网膜病变发生率。与白蛋白尿患者相比,NA-DKD 患者进展为终末期肾病(ESKD)或 eGFR 快速下降的风险较低。与非 DKD 糖尿病患者相比,他们因心力衰竭而死亡和住院的风险增加,但与白蛋白尿型 DKD 相比,风险较低,而不论 GFR 如何。对于这种疾病表型尚无有效的治疗方法,但有限的数据支持使用 SGLT2 抑制剂来减缓慢性肾脏病的进展,同时适当控制代谢危险因素。需要更多的临床研究和病理研究来更好地了解该疾病的表型、预防和治疗方法。DOI: 10.52547/ijkd.7966.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验